Due to Sofdra being a prescription medication, I don't put as much weight on the advertising component.
I look at it as when a doctor sees a patient with hyperhydrosis, there are only a couple of basic 1st generation products to treat with; and then there is the newly approved medication Sofdra, the only new and upgraded 3rd generation medication in existence, proven to be multiples as effective and without the side effects.
Doctors are the most important to communicate this new medication Sofdra too. and the Hyperhydrosis Society will do most of this advocacy for BOT!!
Go BOT!
Ann: Botanix Commercial Day Webinar Presentation, page-126
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.020(5.48%) |
Mkt cap ! $543.4M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 35.5¢ | 34.0¢ | $4.566M | 13.13M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 410003 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 346713 | 8 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| BOT (ASX) Chart |